Crossbow Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $120.0Mattributed |
|---|---|
| Latest round | series-b, $77.0M, 2026-03-01attributed |
| Founded | 2020 |
| Headquarters | Cambridge MA |
| Industry | bio |
| Stage | series-b+ |
| Website | crossbowrx.com |
Crossbow Therapeutics develops T-cell receptor mimic antibodies that target intracellular cancer antigens previously inaccessible to monoclonal therapy. It serves oncology partners and patients with cancers driven by intracellular tumor antigens like MAGE, NY-ESO, and HPV proteins. The TCRm platform extends antibody-style precision into the part of the proteome conventional mAbs cannot reach.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-03-01 | series-b | $77.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $77.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | crossbowrx.com, read 2026-05-02 |
| Description | self-reported | crossbowrx.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.